Translational Psychiatry
November 13, 2025
Bruna Giribaldi Cunha, David Nutt, Marieke Martens et al.
Abstract Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. This study compared psilocybin, with an established antidepressant, escitalopram, to investigate whether there are shared or distinct effects on emotional information processing....
Epigenomics
November 7, 2025
Ivana Leccisotti, M. Moretti, Mario Altamura et al.
AIM Ketamine antidepressant effects go beyond immediate receptor action, involving lasting transcriptional and epigenomic changes that support its rapid, long-lasting benefits. The present systematic review synthesized existing preclinical and clinical evidence on the epigenetic mechanisms of ketamine in the treatment of depression. METHODS A comprehensive search of three electronic databases...
Journal of Advanced Nursing
November 7, 2025
Yingying Qin, Ying Zhou, Wenjing Wang et al.
To explore the abnormal experiences of time and space among transitional-age youth with major depressive disorder. A descriptive phenomenological qualitative study. The study was conducted at a psychiatric hospital in China. Purposive sampling was used to recruit transitional-age youth with major depressive disorder. Data were collected through semi-structured interviews and analysed using...
Neuropharmacology
November 5, 2025
Dimitri Daldegan-Bueno, C Donegan, Rachael Sumner et al.
4 citations
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various mental health disorders. This study evaluated the feasibility and tolerability of an 8-week regimen of microdosed lysergic acid diethylamide (LSD) as a treatment for major depressive disorder in an open-label phase 2A trial (LSDDEP1). Nineteen...
Addictive Behaviors
November 1, 2025
Samantha M Ross-Cypcar, Justin A Haegele, Jeanette M Garcia
While recent nationally representative studies have evaluated the association between hallucinogen use and mental health events, little is known about these associations among disabled adults. Our primary aim was to use national data from the 2021, 2022, and 2023 National Survey on Drug Use and Health (NSDUH) to determine how past-year use of specific hallucinogens is associated with disabled...
International Journal of Drug Policy
November 1, 2025
Liam O Jarvis, Alexander H Jack, Niall Galbraith et al.
1 citation
The global prevalence of depression is high, and there are concerns about the therapeutic effectiveness of current treatments. Research over the past two decades has led to a new class of alternative treatments termed 'psychedelic-assisted therapy (PAT).' This study aimed to investigate the attitudes toward the application and use of psychedelic-assisted therapies in the United Kingdom...
The Brown University Psychopharmacology Update
November 1, 2025
Twice‐weekly dosing of intranasal esketamine resulted in significant improvement in depressive symptoms compared with placebo in adults with treatment‐resistant depression, a 4‐week trial has found. Esketamine doses of 56 and 84 mg both outperformed placebo in the post‐marketing trial. Study results were published online July 2, 2025, in JAMA Psychiatry.
Fortschritte der Neurologie · Psychiatrie
November 1, 2025
Wissenschaftler*innen der polnischen LUXMED Gruppe bewerteten mit einer Metaanalyse die Wirksamkeit und Sicherheit von Psilocybin bei der Behandlung von Major Depressionen (MDD), um die optimale Dosis und den optimalen Zeitpunkt für klinische Studien zu bestimmen.
Journal of Psychiatric Research
November 1, 2025
Felipe Herrmann, Grant Jones, Daniel M Low et al.
Although research shows that psychedelic use may lead to improvement in mental health and well-being, the underlying changes in psychological predictors associated with these improvements remain unclear. 161 participants were recruited in a prospective online survey assessing naturalistic psychedelic use. We used lasso regression to assess how 19 distinct changes in psychological variables...
Psychiatria Polska
October 31, 2025
Katarzyna Kała, Katarzyna Sułkowska‐ziaja, Joanna Piotrowska et al.
Mushrooms of the Amanita genus are considered among the most toxic, causing severe poisoning, often resulting in death. However, of the 707 described species within this genus, only around a dozen contain the toxic octapeptides classified as amanitotoxins and phallotoxins. While most representatives of the genus are considered inedible species, there are a few exceptions that are palatable...